BioCentury
ARTICLE | Finance

Cytokinetics' hearty week

Cytokinetics investors like what they hear from partner Amgen

November 2, 2015 8:00 AM UTC

While investors in Cytokinetics Inc. (NASDAQ:CYTK) did not react strongly to top-line results for omecamtiv mecarbil, they liked what they heard later in the week from Amgen Inc. (NASDAQ:AMGN) about potential plans to advance the molecule into Phase III testing for heart failure.

Amgen hasn't yet made a formal decision about the cardiac myosin activator, but its omecamtiv mecarbil-related comments on last Wednesday's earnings call propelled Cytokinetics to a 26% gain last week, which translated into a $68.6 million gain in market cap...